Cytoskeletal proteins as glioblastoma biomarkers and targets for therapy

ǂa ǂsystematic review

Alja Zottel (Avtor), Ivana Jovchevska (Avtor), Neja Zupanec (Avtor), Radovan Komel (Avtor)

Povzetek

Glioblastoma, the most common primary brain malignancy, is an exceptionally fatal cancer. Lack of suitable biomarkers and efficient treatment largely contribute to the therapy failure. Cytoskeletal proteins are crucial proteins in glioblastoma pathogenesis and can potentially serve as biomarkers and therapeutic targets. Among them, GFAP, has gained most attention as potential diagnostic biomarker, while vimentin and microtubules are considered as prospective therapeutic targets. Microtubules represent one of the best anti-cancer targets due to their critical role in cell proliferation. Despite testing in clinical trials, the efficiency of taxanes, epothilones, vinca-domain binding drugs, colchicine-domain binding drugs and %-tubulin binding drugs remains to be confirmed. Moreover, tumor treating field that disrupts microtubules draw attention because of its high efficiency and is called "the fourth cancer treatment modality". Thereby, because of the involvement of cytoskeleton in key physiological and pathological processes, its therapeutic potential in glioblastoma is currently extensively investigated.

Ključne besede

citoskelet;glioblastom;označevalci;cytoskeleton;glioblastoma;biomarkers;

Podatki

Jezik:	Angleški jezik
Leto izida:	2021
Tipologija:	1.02 - Pregledni znanstveni članek
Organizacija:	UL MF - Medicinska fakulteta
UDK:	616-006
COBISS:	54458627
ISSN:	1879-0461
Št. ogledov:	102
Št. prenosov:	30
Ocena:	0 (0 glasov)
Metapodatki:

Ostali podatki

Sekundarni jezik:	Slovenski jezik
Sekundarne ključne besede:	citoskelet;glioblastom;označevalci;
Vrsta dela (COBISS):	Članek v reviji
Strani:	str. 1-13
Zvezek:	ǂVol. ǂ160
Čas izdaje:	2021
DOI:	10.1016/j.critrevonc.2021.103283
ID:	16129085